Metal‐chelating 3‐hydroxypyrimidine‐2,4‐diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication

[1]  Michael Boeckh,et al.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation , 2017, The New England journal of medicine.

[2]  S. Chou.  A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance , 2017, Antiviral research.

[3]  S. Chou.  Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds , 2017, Antimicrobial Agents and Chemotherapy.

[4]  G. Boivin,et al.  Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes , 2017, Antimicrobial Agents and Chemotherapy.

[5]  Wendy J M van Zuylen,et al.  Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. , 2017, The Lancet. Infectious diseases.

[6]  M. Messerle,et al.  Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation , 2017, Journal of Virology.

[7]  Yan Wang,et al.  Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage , 2016, Journal of Virology.

[8]  Andrew D. Huber,et al.  3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H. , 2016, Journal of medicinal chemistry.

[9]  S. Sarafianos,et al.  Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H. , 2016, Journal of medicinal chemistry.

[10]  S. Sarafianos,et al.  3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations. , 2016, Journal of medicinal chemistry.

[11]  L. Tang,et al.  Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors. , 2016, Biochemistry.

[12]  L. Tang,et al.  Two distinct modes of metal ion binding in the nuclease active site of a viral DNA-packaging terminase: insight into the two-metal-ion catalytic mechanism , 2015, Nucleic acids research.

[13]  S. Chou.  Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance , 2015, Antimicrobial Agents and Chemotherapy.

[14]  S. Sarafianos,et al.  Design, Synthesis, Biochemical, and Antiviral Evaluations of C6 Benzyl and C6 Biarylmethyl Substituted 2-Hydroxylisoquinoline-1,3-diones: Dual Inhibition against HIV Reverse Transcriptase-Associated RNase H and Polymerase with Antiviral Activities , 2014, Journal of medicinal chemistry.

[15]  J. Tavis,et al.  Inhibitors of Nucleotidyltransferase Superfamily Enzymes Suppress Herpes Simplex Virus Replication , 2014, Antimicrobial Agents and Chemotherapy.

[16]  D. Dreyfus,et al.  HIV Integrase Inhibitors Block Replication of Alpha-, Beta-, and Gammaherpesviruses , 2014, mBio.

[17]  H. Zimmermann,et al.  Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure , 2013, Antimicrobial Agents and Chemotherapy.

[18]  J. Baines.  Herpes simplex virus capsid assembly and DNA packaging: a present and future antiviral drug target. , 2011, Trends in microbiology.

[19]  Amina Ahmed.  Antiviral treatment of cytomegalovirus infection. , 2011, Infectious disorders drug targets.

[20]  H. Zimmermann,et al.  The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase , 2011, Journal of Virology.

[21]  E. De Clercq,et al.  A time-of–drug addition approach to target identification of antiviral compounds , 2011, Nature Protocols.

[22]  Y. Pommier,et al.  6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase. , 2011, Bioorganic & medicinal chemistry letters.

[23]  Yves Pommier,et al.  3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase. , 2011, Journal of Medicinal Chemistry.

[24]  S. Chou,et al.  Antiviral Drug Resistance of Human Cytomegalovirus , 2010, Clinical Microbiology Reviews.

[25]  P. Mas,et al.  Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain , 2010, Proceedings of the National Academy of Sciences.

[26]  M. Rossmann,et al.  Genome packaging in viruses. , 2010, Current opinion in structural biology.

[27]  H. Zimmermann,et al.  InVitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246 , 2010, Antimicrobial Agents and Chemotherapy.

[28]  E. De Clercq,et al.  Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus. , 2008, Journal of virological methods.

[29]  S. Bouaziz,et al.  New Functional Domains of Human Cytomegalovirus pUL89 predicted by Sequence Analysis and Three-Dimensional Modelling of the Catalytic Site DEXDc , 2007, Antiviral therapy.

[30]  W. Bresnahan,et al.  Interaction between the Human Cytomegalovirus UL82 Gene Product (pp71) and hDaxx Regulates Immediate-Early Gene Expression and Viral Replication , 2005, Journal of Virology.

[31]  G. Boivin,et al.  Human Cytomegalovirus Resistance to Antiviral Drugs , 2005, Antimicrobial Agents and Chemotherapy.

[32]  F. Baldanti,et al.  Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. , 2004, Human immunology.

[33]  A. Holzenburg,et al.  The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. , 2002, Nucleic acids research.

[34]  J. Trappe,et al.  Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. , 2001, The Journal of antimicrobial chemotherapy.

[35]  H. Klenk,et al.  A Novel Nonnucleoside Inhibitor Specifically Targets Cytomegalovirus DNA Maturation via the UL89 and UL56 Gene Products , 2001, Journal of Virology.

[36]  M. Marschall,et al.  Recombinant Green Fluorescent Protein-Expressing Human Cytomegalovirus as a Tool for Screening Antiviral Agents , 2000, Antimicrobial Agents and Chemotherapy.

[37]  J. Baines,et al.  Proteolytic Cleavage of the Amino Terminus of the UL15 Gene Product of Herpes Simplex Virus Type 1 Is Coupled with Maturation of Viral DNA into Unit-Length Genomes , 1999, Journal of Virology.

[38]  L. Townsend,et al.  Inhibition of Human Cytomegalovirus DNA Maturation by a Benzimidazole Ribonucleoside Is Mediated through the UL89 Gene Product , 1998, Journal of Virology.